Doyle Mittie bought AVTX
February 26, 2026 · Form 4 insider transaction
Doyle Mittie bought 105,000 shares of Avalo Therapeutics, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 4 days after the transaction.
Direction
Acquired (buy-side)
Shares
105,000
Price
$0.00
Total value
N/A
InsiderDoyle Mittie
RoleOfficer, Director
SecurityStock Option (Right to Buy)
Transaction codeA: Grant or award
Transaction dateFebruary 26, 2026
Filing dateMarch 2, 2026
Shares owned after105,000
OwnershipDirect
10b5-1 planNo
AmendedNo
Footnotes
The stock option vests twenty-five percent (25%) on February 26, 2027 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on such vesting date.